Does the media prefer BAX or IRTC?

In the previous week, Baxter International had 18 more articles in the media than iRhythm Technologies. MarketBeat recorded 21 mentions for Baxter International and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.44 beat Baxter International's score of 1.05 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Baxter International 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PEN or IRTC?

In the previous week, Penumbra had 3 more articles in the media than iRhythm Technologies. MarketBeat recorded 6 mentions for Penumbra and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.44 beat Penumbra's score of 1.16 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, IRTC or SNN?

Smith & Nephew SNATS has higher revenue and earnings than iRhythm Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRhythm Technologies $747.14M 4.92 -$44.55M -$0.43 N/A Smith & Nephew SNATS $6.30B 1.83 $625M N/A N/A

Does the media favor IRTC or SNN?

In the previous week, Smith & Nephew SNATS had 5 more articles in the media than iRhythm Technologies. MarketBeat recorded 8 mentions for Smith & Nephew SNATS and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.44 beat Smith & Nephew SNATS's score of 0.06 indicating that iRhythm Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GKOS or IRTC?

In the previous week, Glaukos and Glaukos both had 3 articles in the media. iRhythm Technologies' average media sentiment score of 1.44 beat Glaukos' score of 0.83 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IRTC or GMED?

In the previous week, Globus Medical had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 5 mentions for Globus Medical and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.44 beat Globus Medical's score of 0.55 indicating that iRhythm Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Globus Medical 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

iRhythm Technologies (IRTC) Competitors

$111.43 -1.45 (-1.28%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$111.42 -0.01 (-0.01%)

As of 09/11/2026 07:30 PM Eastern

Compare

IRTC vs. BAX, PEN, SNN, GKOS, and GMED

Should you buy iRhythm Technologies stock or one of its competitors? iRhythm Technologies's main competitors and comparable companies include Baxter International (BAX), Penumbra (PEN), Smith & Nephew SNATS (SNN), Glaukos (GKOS), and Globus Medical (GMED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does iRhythm Technologies compare to Baxter International?

Baxter International (NYSE:BAX) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

iRhythm Technologies has a net margin of -1.69% compared to Baxter International's net margin of -9.27%. Baxter International's return on equity of 16.57% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.27%	16.57%	5.24%
iRhythm Technologies	-1.69%	10.11%	1.53%

Baxter International has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

iRhythm Technologies has lower revenue, but higher earnings than Baxter International. iRhythm Technologies is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.47B	1.07	-$957M	-$2.07	N/A
iRhythm Technologies	$747.14M	4.92	-$44.55M	-$0.43	N/A

Baxter International currently has a consensus target price of $22.45, suggesting a potential downside of 5.67%. iRhythm Technologies has a consensus target price of $179.93, suggesting a potential upside of 61.47%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	2 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

90.2% of Baxter International shares are held by institutional investors. 0.2% of Baxter International shares are held by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Baxter International had 18 more articles in the media than iRhythm Technologies. MarketBeat recorded 21 mentions for Baxter International and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.44 beat Baxter International's score of 1.05 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

iRhythm Technologies beats Baxter International on 11 of the 17 factors compared between the two stocks.

How does iRhythm Technologies compare to Penumbra?

Penumbra (NYSE:PEN) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Penumbra has a net margin of 10.67% compared to iRhythm Technologies' net margin of -1.69%. Penumbra's return on equity of 10.50% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
iRhythm Technologies	-1.69%	10.11%	1.53%

88.9% of Penumbra shares are held by institutional investors. 2.9% of Penumbra shares are held by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Penumbra has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

In the previous week, Penumbra had 3 more articles in the media than iRhythm Technologies. MarketBeat recorded 6 mentions for Penumbra and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.44 beat Penumbra's score of 1.16 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra presently has a consensus price target of $367.07, suggesting a potential upside of 15.48%. iRhythm Technologies has a consensus price target of $179.93, suggesting a potential upside of 61.47%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts clearly believe iRhythm Technologies is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

Penumbra has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.92	$177.69M	$4.07	78.10
iRhythm Technologies	$747.14M	4.92	-$44.55M	-$0.43	N/A

Summary

Penumbra beats iRhythm Technologies on 11 of the 17 factors compared between the two stocks.

How does iRhythm Technologies compare to Smith & Nephew SNATS?

iRhythm Technologies (NASDAQ:IRTC) and Smith & Nephew SNATS (NYSE:SNN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

iRhythm Technologies has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Smith & Nephew SNATS has higher revenue and earnings than iRhythm Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.92	-$44.55M	-$0.43	N/A
Smith & Nephew SNATS	$6.30B	1.83	$625M	N/A	N/A

Smith & Nephew SNATS has a net margin of 0.00% compared to iRhythm Technologies' net margin of -1.69%. iRhythm Technologies' return on equity of 10.11% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
Smith & Nephew SNATS	N/A	N/A	N/A

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

iRhythm Technologies currently has a consensus price target of $179.93, indicating a potential upside of 61.47%. Smith & Nephew SNATS has a consensus price target of $31.91, indicating a potential upside of 16.06%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Smith & Nephew SNATS had 5 more articles in the media than iRhythm Technologies. MarketBeat recorded 8 mentions for Smith & Nephew SNATS and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.44 beat Smith & Nephew SNATS's score of 0.06 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

iRhythm Technologies beats Smith & Nephew SNATS on 9 of the 15 factors compared between the two stocks.

How does iRhythm Technologies compare to Glaukos?

Glaukos (NYSE:GKOS) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Glaukos currently has a consensus target price of $178.08, suggesting a potential upside of 6.41%. iRhythm Technologies has a consensus target price of $179.93, suggesting a potential upside of 61.47%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts plainly believe iRhythm Technologies is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Glaukos and Glaukos both had 3 articles in the media. iRhythm Technologies' average media sentiment score of 1.44 beat Glaukos' score of 0.83 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Glaukos shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Glaukos has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

iRhythm Technologies has higher revenue and earnings than Glaukos. iRhythm Technologies is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	19.45	-$187.69M	-$3.25	N/A
iRhythm Technologies	$747.14M	4.92	-$44.55M	-$0.43	N/A

iRhythm Technologies has a net margin of -1.69% compared to Glaukos' net margin of -30.68%. iRhythm Technologies' return on equity of 10.11% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
iRhythm Technologies	-1.69%	10.11%	1.53%

Summary

iRhythm Technologies beats Glaukos on 11 of the 15 factors compared between the two stocks.

How does iRhythm Technologies compare to Globus Medical?

iRhythm Technologies (NASDAQ:IRTC) and Globus Medical (NYSE:GMED) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

iRhythm Technologies presently has a consensus target price of $179.93, suggesting a potential upside of 61.47%. Globus Medical has a consensus target price of $101.77, suggesting a potential upside of 37.13%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88

Globus Medical has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.92	-$44.55M	-$0.43	N/A
Globus Medical	$2.94B	3.39	$537.87M	$3.91	18.98

95.2% of Globus Medical shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Globus Medical has a net margin of 17.02% compared to iRhythm Technologies' net margin of -1.69%. Globus Medical's return on equity of 14.57% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
Globus Medical	17.02%	14.57%	12.62%

iRhythm Technologies has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Globus Medical has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

In the previous week, Globus Medical had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 5 mentions for Globus Medical and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.44 beat Globus Medical's score of 0.55 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Globus Medical beats iRhythm Technologies on 11 of the 17 factors compared between the two stocks.

Get iRhythm Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRTC vs. The Competition

Export

Metric	iRhythm Technologies	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.72B	$5.38B	$7.13B	$12.72B
Dividend Yield	N/A	1.79%	2.56%	11.15%
P/E Ratio	-259.14	25.09	275.24	25.29
Price / Sales	4.92	82.90	656.02	98.94
Price / Cash	N/A	32.53	77.04	51.44
Price / Book	23.51	5.97	10.33	6.20
Net Income	-$44.55M	$150.75M	$3.50B	$358.50M
7 Day Performance	-9.46%	-2.83%	-3.32%	-2.35%
1 Month Performance	-11.10%	-3.09%	-0.41%	-2.77%
1 Year Performance	-38.03%	9.34%	19.21%	7.63%

iRhythm Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRTC iRhythm Technologies	3.8705 of 5 stars	$111.43 -1.3%	$179.93 +61.5%	-38.4%	$3.72B	$747.14M	N/A	2,400	Positive News
BAX Baxter International	1.4679 of 5 stars	$25.81 +0.9%	$22.45 -13.0%	-2.8%	$13.22B	$11.24B	N/A	37,500	Positive News Analyst Revision
PEN Penumbra	3.5503 of 5 stars	$322.28 +0.4%	$367.07 +13.9%	+14.9%	$12.65B	$1.40B	79.18	4,700	Positive News
SNN Smith & Nephew SNATS	2.7159 of 5 stars	$28.91 +0.8%	$30.93 +7.0%	-28.6%	$12.05B	$6.16B	N/A	16,988	Analyst Downgrade
GKOS Glaukos	1.8078 of 5 stars	$178.20 -1.2%	$178.08 -0.1%	+91.2%	$10.64B	$507.44M	N/A	1,094	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRTC) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iRhythm Technologies (IRTC) Competitors

IRTC vs. BAX, PEN, SNN, GKOS, and GMED

How does iRhythm Technologies compare to Baxter International?

Summary

How does iRhythm Technologies compare to Penumbra?

Summary

How does iRhythm Technologies compare to Smith & Nephew SNATS?

Summary

How does iRhythm Technologies compare to Glaukos?

Summary

How does iRhythm Technologies compare to Globus Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRTC vs. The Competition

iRhythm Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iRhythm Technologies (IRTC) Competitors

IRTC vs. BAX, PEN, SNN, GKOS, and GMED

How does iRhythm Technologies compare to Baxter International?

Is BAX or IRTC more profitable?

Which has more risk and volatility, BAX or IRTC?

Which has better valuation & earnings, BAX or IRTC?

Do analysts prefer BAX or IRTC?

Do institutionals and insiders hold more shares of BAX or IRTC?

Does the media prefer BAX or IRTC?

Summary

How does iRhythm Technologies compare to Penumbra?

Is PEN or IRTC more profitable?

Do insiders and institutionals hold more shares of PEN or IRTC?

Which has more risk & volatility, PEN or IRTC?

Does the media refer more to PEN or IRTC?

Do analysts prefer PEN or IRTC?

Which has better earnings and valuation, PEN or IRTC?

Summary

How does iRhythm Technologies compare to Smith & Nephew SNATS?

Which has more volatility and risk, IRTC or SNN?

Which has higher valuation & earnings, IRTC or SNN?

Is IRTC or SNN more profitable?

Do insiders & institutionals believe in IRTC or SNN?

Do analysts recommend IRTC or SNN?

Does the media favor IRTC or SNN?

Summary

How does iRhythm Technologies compare to Glaukos?

Do analysts recommend GKOS or IRTC?

Does the media prefer GKOS or IRTC?

Do institutionals and insiders hold more shares of GKOS or IRTC?

Which has more volatility and risk, GKOS or IRTC?

Which has stronger earnings & valuation, GKOS or IRTC?

Is GKOS or IRTC more profitable?

Summary

How does iRhythm Technologies compare to Globus Medical?

Do analysts prefer IRTC or GMED?

Which has better earnings & valuation, IRTC or GMED?

Do insiders & institutionals believe in IRTC or GMED?

Is IRTC or GMED more profitable?

Which has more volatility & risk, IRTC or GMED?

Does the media favor IRTC or GMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRTC vs. The Competition

iRhythm Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools